Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas

Launched by CASE COMPREHENSIVE CANCER CENTER · Jun 7, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas," is exploring a new imaging technique called MR fingerprinting. This technique aims to improve the way doctors can see and understand how glioblastomas, which are aggressive brain tumors, spread within the brain. By using MR fingerprinting instead of standard MRI images, the researchers hope to get clearer and more detailed pictures that can help in planning surgery for patients with these tumors.

To participate in this trial, individuals must be over 18 years old and have imaging results that suggest the presence of a glioblastoma with a tumor size larger than 3 cm. They also need to be able to provide written consent and undergo an MRI scan. However, people who have certain conditions that prevent them from having an MRI or surgery, or who have previously been treated for glioblastoma, will not be eligible. If selected, participants can expect to undergo MRI scans to help guide their treatment and potentially improve the outcomes of their surgery. This trial is not yet recruiting participants, but it represents an important step towards improving care for those affected by glioblastoma.

Gender

ALL

Eligibility criteria

• Stage I:
• Inclusion criteria:
• • Age \> 18
• • MR imaging findings suggestive of GB
• • Maximal tumor diameter greater than 3 cm
• • Ability to provide written informed consent
• • Ability to undergo MRI scan
• • Consideration for biopsy, subtotal or gross total resection.
• Exclusion Criteria:
• • Contraindications to MRI
• • Contraindication to surgical treatment
• • Prior treatment for glioblastoma
• Stage II:
• Inclusion Criteria:
• • Age \> 18
• • MR imaging findings suggestive of GB
• • Maximal tumor diameter greater than 3 cm
• • Ability to provide written informed consent
• • Ability to undergo MRI scan
• • Lesions amenable to gross total resection
• • Presence of peritumoral FLAIR signal abnormality beyond the area of enhancement.
• Exclusion Criteria:
• • Inability to undergo MRI imaging
• • Participants undergoing only stereotactic biopsy or less than gross total resection
• • Participants undergoing LITT
• • Inability to consent for the study
• • Previously treated/ recurrent glioma.